Hepatocellular Carcinoma
Conditions
Interventions
experimental group:polylactic acid embolic microspheres
Sponsors
Shanghai Tenth People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Aged 18 to 80 years (including 80 years old), gender is not limited; (2) According to the standard of diagnosis and treatment of primary liver cancer (2018 edition), the clinical stage is primary stage Ia-IIIa; (3) ECOG score <= 2; (4) In the past 2 months, there was no use of chemotherapy, molecular targeted drugs, and Chinese herbal medicines with anticancer effects. (5) No surgery, radiotherapy, ablation and immunotherapy for liver tumors; (6) Good liver function (Child-Pugh A-B grade). (7) The patient was able to understand the purpose of the trial, voluntarily signed the informed consent form, and agreed to receive the last 3 months of imaging follow-up.
Exclusion criteria
Exclusion criteria: (1) Female patients during pregnancy and lactation; (2) white blood cells =10 points; (5) renal dysfunction (creatinine > 2mg / dl or creatinine clearance 51.3umol / L; (9) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 × ULN (upper normal limit) or > 250 U / L, still >= 2 × after liver and antiviral treatment for 1 week ULN; (10) Those who are allergic to contrast agents and embolic agents; (11) The proportion of tumors in the whole liver is >=70%; (12) Patients with central portal vein fistula; (13) Patients who are participating in clinical trials of other drugs or devices.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate of tumor; | — |
Secondary
| Measure | Time frame |
|---|---|
| Surgical success rate;Incidence of severe adverse events (SAE);Alpha-fetoprotein changes; | — |
Countries
China
Contacts
Public ContactLi Maoquan
Shanghai Tenth People's Hospital
Outcome results
None listed